Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625971 · ClinicalTrials.gov registry record
Non-invasive MRD Assessment in Multiple Myeloma
A clinical trial, sponsored by Rajshekhar Chakraborty, MD.
- Completed
- Registry status
- 36
- Enrollment target
NCT05625971: Completed study, sponsored by Rajshekhar Chakraborty, MD.
NCT05625971 is a clinical trial that has completed, run by Rajshekhar Chakraborty, MD. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625971 has completed, sponsored by Rajshekhar Chakraborty, MD.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.
Primary Outcome
MRD assessment includes liquid biopsy and functional imaging.
Interventions
- OTHER MRD Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2025-12-15 |
What the finished NCT05625971 record still lists
NCT05625971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MRD Assessment is the first listed.
NCT05625971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05625971 about?
NCT05625971 is a clinical study titled "Non-invasive MRD Assessment in Multiple Myeloma". The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investig...
What is the current status of trial NCT05625971?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2022-09-14. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT05625971?
The interventions under investigation include: MRD Assessment (OTHER).
Who is sponsoring clinical trial NCT05625971?
This trial is sponsored by Rajshekhar Chakraborty, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI